Ftse Mib
34.474,36
-1,01%
DAX
18.702,72
-0,34%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
70.999,67
-0,63%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Celldex Therapeutics Inc (CLDX) Celldex Therapeutics Inc (CLDX) Notizie

CLDX

Celldex Therapeutics (CLDX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CLDX
DataOraFonteTitoloSimboloCompagnia
15/05/202414:01GlobeNewswire Inc.Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisNASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422:01GlobeNewswire Inc.Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
17/04/202414:01GlobeNewswire Inc.Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
08/03/202413:00GlobeNewswire Inc.Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
05/03/202416:30GlobeNewswire Inc.Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
05/03/202416:10GlobeNewswire Inc.Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CLDXCelldex Therapeutics Inc
01/03/202422:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CLDXCelldex Therapeutics Inc
01/03/202403:14GlobeNewswire Inc.Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common StockNASDAQ:CLDXCelldex Therapeutics Inc
28/02/202422:01GlobeNewswire Inc.Celldex Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:CLDXCelldex Therapeutics Inc
26/02/202413:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CLDXCelldex Therapeutics Inc
26/02/202413:01GlobeNewswire Inc.Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
24/02/202420:05GlobeNewswire Inc.Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
15/02/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
14/02/202422:17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CLDXCelldex Therapeutics Inc
14/02/202418:52Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CLDXCelldex Therapeutics Inc
06/02/202422:01GlobeNewswire Inc.Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
05/02/202414:01GlobeNewswire Inc.Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024NASDAQ:CLDXCelldex Therapeutics Inc
27/11/202322:15GlobeNewswire Inc.Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
08/11/202305:15GlobeNewswire Inc.Celldex Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:CLDXCelldex Therapeutics Inc
06/11/202312:30GlobeNewswire Inc.Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
05/11/202321:00GlobeNewswire Inc.Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg BarzolvolimabNASDAQ:CLDXCelldex Therapeutics Inc
03/11/202321:01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:CLDXCelldex Therapeutics Inc
02/11/202321:01GlobeNewswire Inc.Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
26/09/202313:01GlobeNewswire Inc.Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023NASDAQ:CLDXCelldex Therapeutics Inc
25/09/202314:31GlobeNewswire Inc.Celldex Therapeutics to Present at Cantor Global Healthcare ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
08/08/202322:01GlobeNewswire Inc.Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
11/07/202314:01GlobeNewswire Inc.Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
06/07/202314:01GlobeNewswire Inc.Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic EsophagitisNASDAQ:CLDXCelldex Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CLDX

La tua Cronologia

AQSE
TRCS.GB
Tracsis
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network